Trastuzumab Binding Protein For In-Process Monitoring Of Antibody Drug Conjugates (ADC)
Orla Protein Technologies Ltd. (Orla) announces a new trastuzumab-binding protein for simplified assay of trastuzumab binding to its antigen during development and manufacture of Antibody Drug Conjugates (ADC). The trastuzumab-binding protein (ORLA254) incorporates the Her2 antigen into Orla’s proprietary surface binding unit (SBU).
Tools that allow developers to monitor the effects of reaction conditions on target binding can be key for decision making in method development for ADC production and subsequently for monitoring scale-up. The trastuzumab binding protein has been specially designed to meet this requirement and incorporates easy immobilisation and application across multiple platforms such as ELISA and bioanalytical instruments such as Biacore and Octet.
ORLA254 was developed for a project with ADC developer Glythera. Dr Jenny Thirlway, Technical Director at Glythera, explains, “We were looking for a simple in-process tool to monitor ADC binding. Methods to test ADC functionality are generally time consuming and expensive. Assays using Orla’s protein accelerated optimisation and assisted in decision making by quickly establishing whether a specific reaction condition affects ADC binding.”
Using ORLA254 on ELISA plates, Glythera were able to screen many reaction conditions for their effect on binding of trastuzumab to its target. For example, data gained on the effect of solvent concentration on target binding allowed for limits to be set on solvent concentrations. The binding profiles correlated with cell kill profiles.
Customers can purchase ORLA254 as solution or precoated ELISA plates. Either format enables scientists to quickly and easily test the effect of reaction conditions on the ability of processed trastuzumab to bind its target antigen and speed up the ADC method development.
Orla is expanding its range of antibody binding proteins for similar assays for a variety of medicinal antibodies. A custom protein design service is available for the development of specific antibody binding proteins for custom targets.